0
ARTICLE |

Captopril and Membranous Glomerulopathy FREE

Edmund J. Lewis, MD
JAMA. 1984;252(7):900-900. doi:10.1001/jama.1984.03350070018012
Text Size: A A A
Published online

To the Editor.—  A variety of reports of ultrastructural and immunopathologic changes in the renal glomerulus and of proteinuria and membranous glomerulonephritis have been related to the use of captopril. However, many of the abnormalities originally attributed to captopril have been found in the glomeruli of hypertensive persons who had never received this drug.1 The chemical structure of captopril has raised many suspicions with regard to potential side effects. There has been a tendency to equate the chemical structure of captopril with that of penicillamine, by virtue of their sulfhydryl groups, which has contributed greatly to the suspicions of toxicity surrounding the drug. However, with respect to possible glomerular damage, the safety profile of enalapril, an angiotensin-converting enzyme inhibitor that does not contain a sulfhydryl moiety, reveals that proteinuria occurs as frequently with that drug (1.4%) as it does among those treated with captopril (1.2%) and among hypertensive patients

REFERENCES

Captopril Collaborative Study Group:  Does captopril cause renal damage in hypertensive patients? Lancet 1982;;1:988-990.
Tempero KF, Kramsch DM, Moncloa F:  The safety profile of enalopril . Proceedings of the 17th International Congress of Therapy, Rome, Sept 27-30,1983 .
Sturgill BC, Shearlock KT:  Membranous glomerulopathy and nephrotic syndrome with captopril therapy . JAMA 1983;;250:2343-2345.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Captopril Collaborative Study Group:  Does captopril cause renal damage in hypertensive patients? Lancet 1982;;1:988-990.
Tempero KF, Kramsch DM, Moncloa F:  The safety profile of enalopril . Proceedings of the 17th International Congress of Therapy, Rome, Sept 27-30,1983 .
Sturgill BC, Shearlock KT:  Membranous glomerulopathy and nephrotic syndrome with captopril therapy . JAMA 1983;;250:2343-2345.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.